This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.ABSTRACT I. HYPOTHESIS Important issues must be considered when providing treatment to pregnant women who intend to discontinue treatment postpartum.
The aim of this trial is to examine the safety and efficacy of treatment with three NRTIs versus two NRTIs and one PI. The hypothesis is treating pregnant women who do not meet the current PHS guidelines for initiation of therapy (and would not start treatment if they were not pregnant) with an all NRTI regimen (abacavir/lamivudine/zidovudine) will 1) reduce the risk of maternal to child transmission of HIV to the lowest attainable level, 2) minimize the risk of fetal toxicity and maternal drug side effects, 3) preserve therapeutic options for the mother for the future and 4) minimize the likelihood of developing resistance to antiretrovirals used during pregnancy and in the future.II.
SPECIFIC AIMS Primary To examine the safety and efficacy of treatment with three NRTIs versus two NRTIs and one PI, by comparing the proportion of women in group A and B with virologic suppression to < 400 copies per mL at 34 weeks gestation (or the last viral load prior to delivery if this occurs < 34 weeks), while continuing on assigned therapy.Secondary 1. To compare HIV-related health status of women at delivery by CD4+ lymphocyte counts and plasma HIV-1 viral load. 2. To describe adherence to therapy among women in Groups A and B.3. To assess the HIV- related health status of women postpartum as determined by CD4+lymphocyte counts and plasma HIV-1 viral load at 3, 6, and 12 months postpartum, and prior to the initiation of any new antiretroviral therapy.4. To compare the development of HIV-1 genotypic resistance among women in Group A and Group B at the time of delivery, and at 3, 6, and 12 months postpartum and in all cases of treatment failure and prior to the initiation of any new antiretroviral therapy.5. To compare the incidence of abnormal glucose tolerance, gestational diabetes and abnormal lactate levels during pregnancy between Group A and B.6. To compare the incidence of adverse outcomes among infants born to women in Group A and B, including: anemia, hypoglycemia and abnormal liver function studies, prematurity, and low birth weight, perinatal HIV transmission. 7. To evaluate retrospectively the predictive value, sensitivity and specificity of polymorphisms in HLA-B57, HLA-DR7 and HLA-DQ3 in identifying pregnant women at risk for development of abacavir hypersensitivity. 8. To determine the peak concentration and area under the curve (AUC) of lopinavir/ritonavir (533/133 mg taken PO Q12H) in the first 12 women enrolled in Group B at steady-state in the third trimester of pregnancy (see section 9.0). 9. To compare the concentration of T-cell receptor-rearrangement excision DNA circles (TREC) in Group A and B at entry, delivery, and at 6 weeks postpartum.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000188-44
Application #
7717667
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2007-12-01
Project End
2008-11-30
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
44
Fiscal Year
2008
Total Cost
$1,593
Indirect Cost
Name
Baylor College of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Hunsaker, Sanita L; Garland, Beth H; Rofey, Dana et al. (2018) A Multisite 2-Year Follow Up of Psychopathology Prevalence, Predictors, and Correlates Among Adolescents Who Did or Did Not Undergo Weight Loss Surgery. J Adolesc Health 63:142-150
Lanzieri, Tatiana M; Chung, Winnie; Leung, Jessica et al. (2018) Hearing Trajectory in Children with Congenital Cytomegalovirus Infection. Otolaryngol Head Neck Surg 158:736-744
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Michalsky, Marc P; Inge, Thomas H; Jenkins, Todd M et al. (2018) Cardiovascular Risk Factors After Adolescent Bariatric Surgery. Pediatrics 141:
Lau, Chantal (2018) Breastfeeding Challenges and the Preterm Mother-Infant Dyad: A Conceptual Model. Breastfeed Med 13:8-17
Gururangan, Sridharan; Reap, Elizabeth; Schmittling, Robert et al. (2017) Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11). Cancer Immunol Immunother 66:1589-1595
Lanzieri, T M; Leung, J; Caviness, A C et al. (2017) Long-term outcomes of children with symptomatic congenital cytomegalovirus disease. J Perinatol 37:875-880
El-Hattab, Ayman W; Zarante, Ana Maria; Almannai, Mohammed et al. (2017) Therapies for mitochondrial diseases and current clinical trials. Mol Genet Metab 122:1-9
Jin, Haoxing Douglas; Demmler-Harrison, Gail J; Coats, David K et al. (2017) Long-term Visual and Ocular Sequelae in Patients With Congenital Cytomegalovirus Infection. Pediatr Infect Dis J 36:877-882
Oh, Sam S; Du, Randal; Zeiger, Andrew M et al. (2017) Breastfeeding associated with higher lung function in African American youths with asthma. J Asthma 54:856-865

Showing the most recent 10 out of 459 publications